

Wendy Y Cheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6358331/publications.pdf>

Version: 2024-02-01

48
papers

389
citations

759233

12
h-index

794594

19
g-index

48
all docs

48
docs citations

48
times ranked

608
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Newly Treated Korean Patients With Asthma: A Retrospective Cohort Study. <i>Allergy, Asthma and Immunology Research</i> , 2022, 14, 220.	2.9	3
2	Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation. <i>Journal of Medical Economics</i> , 2022, 25, 367-380.	2.1	4
3	Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population. <i>ClinicoEconomics and Outcomes Research</i> , 2022, Volume 14, 357-369.	1.9	9
4	Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA. <i>Child's Nervous System</i> , 2022, , .	1.1	3
5	Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes. <i>Hematology</i> , 2021, 26, 261-270.	1.5	3
6	Health-related quality of life (HRQoL) among pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States (U.S.). <i>Journal of Clinical Oncology</i> , 2021, 39, 10042-10042.	1.6	0
7	Development and Validation of a Healthcare Utilization-Based Algorithm to Identify Acute Exacerbations of Chronic Obstructive Pulmonary Disease. <i>International Journal of COPD</i> , 2021, Volume 16, 1687-1698.	2.3	1
8	RARE-06. CLINICAL BURDEN AMONG PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND PLEXIFORM NEUROFIBROMA (PN) IN THE UNITED STATES (US). <i>Neuro-Oncology</i> , 2021, 23, i41-i42.	1.2	0
9	Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population. <i>Advances in Therapy</i> , 2021, 38, 4461-4479.	2.9	16
10	Increased Health Care Resource Utilization and Costs Associated with Herpes Zoster Among Patients Aged ≥50 Years with Chronic Obstructive Pulmonary Disease in the United States. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 502-516.	0.7	4
11	Real-World Ravulizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population. <i>Blood</i> , 2021, 138, 4999-4999.	1.4	0
12	Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study. <i>Blood</i> , 2021, 138, 3646-3646.	1.4	0
13	QOLP-02. HEALTH-RELATED QUALITY OF LIFE (HRQOL) AMONG PEDIATRIC PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND PLEXIFORM NEUROFIBROMA (PN) IN THE UNITED STATES: PERSPECTIVES OF THE PATIENTS AND CAREGIVERS. <i>Neuro-Oncology</i> , 2021, 23, vi182-vi183.	1.2	0
14	Determinants of Meningococcal ACWY vaccination in adolescents in the US: completion and compliance with the CDC recommendations. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 176-188.	3.3	8
15	<p>Direct and Indirect Costs of Infectious Conjunctivitis in a Commercially Insured Population in the United States</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 377-387.	1.8	10
16	24. Economic Burden of Herpes Zoster Among Individuals with Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, S35-S36.	0.9	1
17	Real-World Treatment Patterns and Healthcare Resource Utilization (HRU) of Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population. <i>Blood</i> , 2020, 136, 15-16.	1.4	1
18	Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population. <i>Blood</i> , 2020, 136, 13-13.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study. <i>Journal of Drug Assessment</i> , 2019, 8, 150-158.	2.2	1
20	Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5120-5135.	3.6	29
21	Development of a classifier to identify patients with probable Lennoxâ€“Gastaut syndrome in health insurance claims databases via random forest methodology. <i>Current Medical Research and Opinion</i> , 2019, 35, 1415-1420.	1.9	4
22	Clinical burden of asynchrony in patients with asthma when using metered-dose inhalers for control. <i>Allergy and Asthma Proceedings</i> , 2019, 40, 21-31.	2.2	4
23	Epidemiologic and clinical characteristics of nontransfusionâ€“dependent thalassemia in the United States. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27067.	1.5	15
24	Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 257-265.	0.4	39
25	Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets. <i>Current Medical Research and Opinion</i> , 2018, 34, 1959-1966.	1.9	7
26	Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 50-57.	1.9	19
27	2459. Meningococcal ACWY (MenACWY) Vaccination of Adolescents in the United States: How Compliant Are We With the Advisory Committee on Immunization Practices (ACIP) Recommendations?. <i>Open Forum Infectious Diseases</i> , 2018, 5, S737-S737.	0.9	0
28	Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 500.e1-500.e9.	1.6	41
29	Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication. <i>BMC Infectious Diseases</i> , 2018, 18, 438.	2.9	8
30	Hepatitis A, B, and A/B vaccination series completion among US adults: A claims-based analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1-6.	3.3	11
31	Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study. <i>American Health and Drug Benefits</i> , 2018, 11, 97-106.	0.5	6
32	Assessment of treatment patterns and healthcare costs associated with probable Lennoxâ€“Gastaut syndrome. <i>Epilepsy and Behavior</i> , 2017, 73, 46-50.	1.7	24
33	Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. <i>Medical Oncology</i> , 2017, 34, 160.	2.5	11
34	Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices.. <i>Journal of Clinical Oncology</i> , 2017, 35, 214-214.	1.6	2
35	Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 413-421.	1.9	1
36	Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia. <i>Journal of Medical Economics</i> , 2016, 19, 292-303.	2.1	27

#	ARTICLE	IF	CITATIONS
37	A Meta-Analysis and Meta-Regression of the Efficacy of Front-Line Treatment Combinations with Ponatinib Versus 1st- and 2nd-Generation Tyrosine Kinase Inhibitors for Ph+ Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 5189-5189.	1.4	0
38	Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 2803-2811.	1.3	3
39	Development of a shared decision-making tool to assist patients and clinicians with decisions on oral anticoagulant treatment for atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2015, 31, 2261-2272.	1.9	17
40	Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States. <i>Blood</i> , 2015, 126, 3279-3279.	1.4	1
41	Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs. <i>Journal of Opioid Management</i> , 2015, 11, 199-210.	0.5	17
42	Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16029-e16029.	1.6	0
43	Assessing the prognostic impact of intermediate outcomes on survival time in relapsed/refractory multiple myeloma (RRMM) patients (pts) via a robust and clinically interpretable quantitative procedure.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17743-e17743.	1.6	0
44	Treatment patterns and characteristics of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11502-e11502.	1.6	0
45	Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives. <i>Tremor and Other Hyperkinetic Movements</i> , 2014, 4, 224.	2.0	24
46	HD-PRO-TRIADâ„¢ Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease. <i>Tremor and Other Hyperkinetic Movements</i> , 2014, 4, 223.	2.0	13
47	Adherence to Iron Chelation Therapy and Associated Healthcare Resource Utilization and Costs in Medicaid Patients with Sickle Cell Disease. <i>Blood</i> , 2014, 124, 2177-2177.	1.4	0
48	Medical Complications In Patients With Myelofibrosis By Frequency Of Blood Transfusion and Iron Chelation Therapy. <i>Blood</i> , 2013, 122, 2964-2964.	1.4	0